SPOTLIGHT: Thailand reconsiders compulsory licenses

Thailand's new public health minister has pledged to review his country's compulsory licensing of four cancer medicines--two made by Novartis, one by Sanofi-Aventis, and another by Roche. Under the previous minister, Thailand was aggressively using compulsory licenses to circumvent patent protection on drugs so it could obtain lower-cost versions. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.